103 related articles for article (PubMed ID: 15357981)
1. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
[TBL] [Abstract][Full Text] [Related]
2. Thienopyridine urea inhibitors of KDR kinase.
Heyman HR; Frey RR; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Soni NB; Marcotte PA; Pease LJ; Glaser KB; Yates M; Bouska JJ; Albert DH; Black-Schaefer CL; Dandliker PJ; Stewart KD; Rafferty P; Davidsen SK; Michaelides MR; Curtin ML
Bioorg Med Chem Lett; 2007 Mar; 17(5):1246-9. PubMed ID: 17188869
[TBL] [Abstract][Full Text] [Related]
3. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
4. KDR inhibitor with the intramolecular non-bonded interaction: conformation-activity relationships of novel indole-3-carboxamide derivatives.
Honda T; Nagahara H; Mogi H; Ban M; Aono H
Bioorg Med Chem Lett; 2011 Mar; 21(6):1782-5. PubMed ID: 21324683
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
[TBL] [Abstract][Full Text] [Related]
6. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
[TBL] [Abstract][Full Text] [Related]
7. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
Zhao G; Peery RB; Yingling JM
Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
[TBL] [Abstract][Full Text] [Related]
8. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationship and classification analysis of diaryl ureas against vascular endothelial growth factor receptor-2 kinase using linear and non-linear models.
Sun M; Chen J; Wei H; Yin S; Yang Y; Ji M
Chem Biol Drug Des; 2009 Jun; 73(6):644-54. PubMed ID: 19635056
[TBL] [Abstract][Full Text] [Related]
11. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
13. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
Wu Z; Fraley ME; Bilodeau MT; Kaufman ML; Tasber ES; Balitza AE; Hartman GD; Coll KE; Rickert K; Shipman J; Shi B; Sepp-Lorenzino L; Thomas KA
Bioorg Med Chem Lett; 2004 Feb; 14(4):909-12. PubMed ID: 15012992
[TBL] [Abstract][Full Text] [Related]
15. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
[TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: a novel class of KDR kinase inhibitors.
Kuethe JT; Wong A; Qu C; Smitrovich J; Davies IW; Hughes DL
J Org Chem; 2005 Apr; 70(7):2555-67. PubMed ID: 15787543
[TBL] [Abstract][Full Text] [Related]
19. Exploring novel KDR inhibitors based on pharmaco-informatics methodology.
Kar RK; Suryadevara P; Sahoo BR; Sahoo GC; Dikhit MR; Das P
SAR QSAR Environ Res; 2013; 24(3):215-34. PubMed ID: 23437769
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.
Foster KA; Regan HK; Danziger AP; Detwiler T; Kwon N; Rickert K; Lynch JJ; Regan CP
Neurosci Res; 2009 Jan; 63(1):10-6. PubMed ID: 18951929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
